Tech Center 1600 • Art Units: 1649 1675
This examiner grants 54% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17914121 | COMPOSITIONS AND METHODS FOR TREATING A NEURODEGENERATIVE OR DEVELOPMENTAL DISORDER | Non-Final OA | The Regents of the University of California |
| 17744614 | ANTIGENIC NEURON SPECIFIC ENOLASE PEPTIDES FOR DIAGNOSING AND TREATING AUTISM | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17476078 | Use of LEPR Agonists for Pain | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17769165 | MUSCLE REGENERATION AND GROWTH | Non-Final OA | Brown University |
| 17980435 | BLOOD-BASED SCREEN FOR DETECTING NEUROLOGICAL DISEASES IN PRIMARY CARE SETTINGS | Non-Final OA | Board of Regents, The University of Texas System |
| 18657340 | CITRULLINATED BRAIN AND NEUROLOGICAL PROTEINS AS BIOMARKERS OF BRAIN INJURY OR NEURODEGENERATION | Final Rejection | THE JOHNS HOPKINS UNIVERSITY |
| 18028932 | PEPTIDE FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Non-Final OA | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 17778061 | Anti-Alpha-Synuclein Monoclonal Antibodies, and Methods Using Same | Final Rejection | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17996498 | PROTEIN MARKERS FOR ASSESSING ALZHEIMER'S DISEASE | Non-Final OA | The Hong Kong University of Science and Technology |
| 17775605 | BIOMARKERS FOR THE PREDICTION AND IDENTIFICATION OF PARKINSON'S DISEASE | Non-Final OA | Oxford University Innovation Limited |
| 17747397 | METHODS OF EVALUATING BRAIN INJURY IN A PEDIATRIC SUBJECT | Final Rejection | Abbott Laboratories |
| 18776405 | USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES FOR THE TREATMENT AND DIAGNOSIS OF MOOD DISORDERS | Non-Final OA | Neuracle Science Co., Ltd. |
| 18773152 | METHODS FOR EVALUATING AND IMPROVING COGNITIVE FUNCTION | Non-Final OA | THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH |
| 18770847 | THERAPEUTIC AGENT COMPOSITION AND METHOD OF USE, FOR TREATING, RELIEVING, OR ALLEVIATING ALZHEIMER'S DISEASE | Non-Final OA | BIOMED INDUSTRIES, INC. |
| 17767014 | METHOD FOR DETECTING LUPUS NEPHRITIS | Non-Final OA | Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen |
| 18246193 | COMPOSITION FOR PREVENTING OR TREATING DEMENTIA, CONTAINING PEPTIDE NUCLEIC ACID COMPLEX AS ACTIVE INGREDIENT | Non-Final OA | SEASUN THERAPEUTICS |
| 17048059 | MODULATING IMMUNE RESPONSE VIA TARGETING OF OLFACTORY RECEPTOR ACTIVITY | Non-Final OA | La Jolla Institute for Allergy and Immunology |
| 17907624 | THERAPEUTIC AGENTS, PHARMACEUTICAL COMPOSITIONS, AND ASSOCIATED BIOMARKERS BASED ON TRK-B | Non-Final OA | FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA |
| 17934660 | PREDICTIVE OUTCOME PROFILING FOR USE OF AN ANTI-SEMAPHORIN-4D BINDING MOLECULE TO TREAT NEURODEGENERATIVE DISORDERS | Non-Final OA | VACCINEX, INC. |
| 17812916 | METHODS AND KITS FOR DIAGNOSING MILD COGNITIVE IMPAIRMENT | Final Rejection | Far Eastern Memorial Hospital |
| 17119776 | CHANNEL MODULATORS | Non-Final OA | OCUNEXUS THERAPEUTICS, INC. |
| 17544007 | METHODS AND COMPOSITIONS FOR DIAGNOSING NEURODEGENERATIVE DISEASE | Final Rejection | Board of the Regents of the University of Nebraska |
| 17515269 | SYSTEM AND METHOD FOR TESTING EFFECTS OF CHEMICAL COMPOUNDS ON COGNITIVE FUNCTION | Final Rejection | CCLabs Pty Ltd |
| 16312346 | Blood Test for Screening Out Amyloid and Alzheimers Disease Presence | Final Rejection | University of North Texas Health Science Center at Fort Worth |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy